47. Xiao B, Fan S, Zeng Z, et al. Purification of novel UBAP1 protein and its decreased expression on nasopharyngeal carcinoma tissue microarray. Protein Expr Purif, 2006, 47: 60-67？
[2]
48. Chalhoub N, Baker S J. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol, 2009, 4: 127-150？
[3]
49. Shen G P, Pan Q H, Hong M H, et al. Human genetic variants of homologous recombination repair genes first found to be associated with Epstein-Barr virus antibody titers in healthy cantonese. Int J Cancer, 2010
[4]
51. Guo Y, Chen J X, Yang S, et al. Selection of reliable reference genes for gene expression study in nasopharyngeal carcinoma. Acta Pharmacol Sin, 2010, 31: 1487-1494？
[5]
52. Xu Y F, Liu W L, Dong J Q, et al. Sequencing of DC-SIGN promoter indicates an association between promoter variation and risk of nasopharyngeal carcinoma in Cantonese. BMC Med Genet, 2010
[6]
53. Wang S, Xiao X, Zhou X, et al. TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer, 2010
[7]
57. Jang Y J, Ji J H, Choi Y C, et al. Regulation of Polo-like kinase 1 by DNA damage in mitosis: Inhibition of mitotic PLK-1 by protein phosphatase 2A. J Biol Chem, 2007, 282: 2473-2482？
[8]
59. Syljuasen R G, Jensen S, Bartek J, et al. Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Res, 2006, 66: 10253-10257？
[9]
60. Spankuch B, Kurunci-Csacsko E, Kaufmann M, et al. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene, 2007, 26: 5793-5807？
[10]
61. Su S F, Han F, Zhao C, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys, 2010
[11]
63. Shai E, Varon D. Development, cell differentiation, angiogenesis—Microparticles and their roles in angiogenesis. Arterioscler Thromb Vasc Biol, 2011, 31: 10-14？
[12]
64. Lv X, Xiang Y Q, Cao S M, et al. Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: More distant metastases and shorter overall survival after treatment. Head Neck, 2010
[13]
65. Hua Z, Lv Q, Ye W B, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One, 2006, 1: e116？
[14]
68. Chew M M, Gan S Y, Khoo A S, et al. Interleukins, laminin and Epstein-Barr virus latent membrane protein 1 (EBV LMP1) promote metastatic phenotype in nasopharyngeal carcinoma. BMC Cancer, 2010, 10: 574
[15]
71. Xia H, Ng S S, Jiang S, et al. MiR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun, 2010, 391: 535-541？
[16]
2. Chin D, Boyle G M, Porceddu S, et al. Head and neck cancer: Past, present and future. Expert Rev Anticancer Ther, 2006, 6: 1111-1118？
[17]
3. Deyrup A T. Epstein-Barr virus-associated epithelial and mesenchymal neoplasms. Hum Pathol, 2008, 39: 473-483？
[18]
4. Zhu J Y, Pfuhl T, Motsch N, et al. Identification of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. J Virol, 2009, 83: 3333-3341？
[19]
5. Georgia S. Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA, 2009, 15: 1443-1461？
[20]
6. Filipowicz W, Bhattacharyya S N, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet, 2008, 9: 102-114
[21]
10. Wu M, Jolicoeur N, Li Z, et al. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis, 2008, 29: 1710-1716？
[22]
11. Kumar M S, Lu J, Mercer K L, et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genet, 2007, 39: 673-677？
[23]
15. Finoux A L, Chartrand P. Oncogenic and tumour suppressor microRNAs. Med Sci (Paris), 2008, 24: 1049-1054
[24]
16. Wang X, Tang S, Le S Y, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One, 2008, 3: e2557？
[25]
19. Takakura S, Mitsutake N, Nakashima M, et al. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci, 2008, 99: 1147-1154？
[26]
20. Welch C, Chen Y, Stallings R L. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene, 2007, 26: 5017-5022？
[27]
21. Douglas R H. Metastamir: The field of metastasis-regulatory microRNA is spreading. Cancer Res, 2009, 69: 7495-7498？
[28]
22. Cosmopoulos K, Pegtel M, Hawkins J, et al. Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol, 2009, 83: 2357-2367？
[29]
23. Griffiths-Jones S, Saini H K, van Dongen S, et al. miRBase: Tools for microRNA genomics. Nucleic Acids Res, 2008, 36: D154-D158？
[30]
24. Gourzones C, Gelin A, Bombik I, et al. Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells. Virol J, 2010, 7: 271？
[31]
28. Cullen B R. Viral and cellular messenger RNA targets of viral microRNAs. Nature, 2009, 457: 421-425？
[32]
30. Choy E Y, Siu K L, Kok K H, et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med, 2008, 205: 2551-2560？
[33]
32. Chang L K, Chuang J Y, Nakao M, et al. MCAF1 and synergistic activation of the transcription of Epstein-Barr virus lytic genes by Rta and Zta. Nucleic Acids Res, 2010, 38: 4687-4700？
[34]
33. Hariwiyanto B, Sastrowiyoto S, Mubarika S, et al. LMP1 and LMP2 may be prognostic factors for outcome of therapy in nasopharyngeal cancers in Indonesia. Asian Pac J Cancer Prev, 2010, 11: 763-766
[35]
34. Natalie M, Thorsten P, Jan M, et al. Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a. RNA Biol, 2007, 4: 131-137
[36]
36. Graziana G, Annalisa R, Daniela R, et al. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-κB pathway. Nucleic Acids Res, 2008, 36: 6608-6619？
[37]
37. Lo A K, To K F, Lo K W, et al. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci USA, 2007, 104: 16164-16169？
[38]
38. Zheng H, Li L L, Hu D S, et al. Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol, 2007, 4: 185-196
[39]
40. Chen H C, Chen G H, Chen Y H, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer, 2009, 100: 1002-1011？
[40]
41. Li Y H, Hu C F, Shao Q, et al. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med, 2008, 6: 1？
[41]
42. Pan J, Kong L, Lin S, et al. The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma. Laryngoscope, 2008, 118: 1970-1975？
[42]
43. Zeng Z Y, Zhou Y H, Zhang W L, et al. Gene expression profiling of nasopharyngeal carcinoma reveals the abnormally regulated Wnt signaling pathway. Hum Pathol, 2007, 38: 120-133？
[43]
1. George A C, Carlo M C. MicroRNA signatures in human cancers. Nat Rev Cancer, 2006, 6: 857-866？
[44]
7. Israel A, Sharan R, Ruppin E, et al. Increased microRNA activity in human cancers. PLoS One, 2009, 4: e6045？
[45]
8. Olson P, Lu J, Zhang H, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev, 2009, 23: 2152-2165？
[46]
9. Zhang B, Pan X, Cobb G P, et al. MicroRNAs as oncogenes and tumor suppressors. Dev Biol, 2007, 302: 1-12？
[47]
12. Liu C G, Calin G A, Volinia S, et al. MicroRNA expression profiling using microarrays. Nat Protoc, 2008, 3: 563-578？
[48]
13. Hatfield S, Ruohola-Baker H. microRNA and stem cell function. Cell Tissue Res, 2008, 331: 57-66？
[49]
14. Bushati N, Cohen S M. microRNA functions. Annu Rev Cell Dev Biol, 2007, 23: 175-205？
[50]
17. Aurora E K, Frank J S. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer, 2006, 6: 259-269？
[51]
18. Rai D, Karanti S, Jung I, et al. Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet, 2008, 181: 8-15？
[52]
25. Jing Y Z, Wang Y, Jia Y P, et al. Polymorphisms of Epstein-Barr virus BHRF1 gene, a homologue of bcl-2. Chin J Cancer, 2010, 29: 1000-1005
[53]
26. Edwards R H, Marquitz A R, Raab-Traub N. Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. J Virol, 2008, 82: 9094-9106？
[54]
27. Ghosh Z, Mallick B, Chakrabarti J. Cellular versus viral microRNAs in host-virus interaction. Nucleic Acids Res, 2009, 37: 1035-1048？
[55]
29. Xia T, O'Hara A, Araujo I, et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res, 2008, 68: 1436-1442？
[56]
31. Iizasa H, Wulff B E, Alla N R, et al. Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J Biol Chem, 2010, 285: 33358-33370？
[57]
35. Middeldorp J M, Pegtel D M. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape. Semin Cancer Biol, 2008, 18: 388-396？
[58]
39. Liu Q, Fu H, Sun F, et al. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res, 2008, 36: 5391-5404？
[59]
44. Zhang L M, Deng T, Li X Y, et al. MicroRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. Carcinogenesis, 2010, 31: 559-566？
[60]
45. Zhou H D, Li X L, Li G Y, et al. Effect of SPLUNC1 protein on the Pseudomonas aeruginosa and Epstein-Barr virus. Mol Cell Biochem, 2008, 309: 191-197？
[61]
46. Nakada C, Matsuura K, Tsukamoto Y, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: Significant down-regulation of miR-141 and miR-200c. J Pathol, 2008, 216: 418-427？
[62]
50. Ran Y, Wu S, You Y. Demethylation of E-cadherin gene in nasopharyngeal carcinoma could serve as a potential therapeutic strategy. J Biochem, 2010
[63]
54. Strebhardt K, Ullrich A. Targeting Polo-like kinase 1 for cancer therapy. Nat Rev Cancer, 2006, 6: 321-330？
[64]
55. Wei S, Nehad M A, Carlo B, et al. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer, 2010, 126: 2036-2048
[65]
56. Liu X, Lei M, Erikson R L. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol, 2006, 26: 2093-2108
[66]
58. Sun F, Mikuni S, Kinjo M. Monitoring the caspase cascade in single apoptotic cells using a three-color fluorescent protein substrate. Biochem Biophys Res Commun, 2010
[67]
62. Zhao L, Wan Q, Zhou Y, et al. The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiother Oncol, 2010
[68]
66. Olsson A K, Dimberg A, Kreuger J, et al. VEGF receptor signalling—in control of vascular function. Nat Rev Mol Cell Biol, 2006, 7: 359-371？
[69]
67. Li G, Wu Z R, Peng Y, et al. MicroRNA-10b induced by Epstein-Barr virus-encoded latent membrane protein-1 promotes the metastasis of human nasopharyngeal carcinoma cells. Cancer Lett, 2010, 299: 29-36？
[70]
69. Kim T J, Lee Y S, Kang J H, et al. Prognostic significance of expression of vegf and cox-2 in nasopharyngeal carcinoma and its association with expression of C-erbB2 and EGFR. J Surg Oncol, 2010
[71]
70. Sikumar S, Johan A B, Chen I H, et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracelluar matrix proteins. Proc Natl Acad Sci USA, 2008, 105: 5874-5878？
[72]
72. Chen L C, Chen C C, Liang Y, et al. A novel role for TNFAIP2: Its correlation with invasion and metastasis in nasopharyngeal carcinoma. Mod Pathol, 2010
